Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Wang

Showing results (151-160 of 167) with videos related to

Pageof 17
Sort By:
Cancer Cell|January 4, 2016
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth SuppressionTikvah K Hayes, Nicole F Neel, Chaoxin Hu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2019
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)Dung T Le, Vincent J Picozzi, Andrew H Ko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2022
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion StudyAndrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, et al.
The Lancet. Oncology|April 9, 2016
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trialTimothy M Nywening, Andrea Wang-Gillam, Dominic E Sanford, et al.
Cancer Communications (London, England)|October 2, 2025
Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trialsJian Li, Ting Deng, Yanhong Gu, et al.
Oncotarget|March 31, 2018
Dynamic changes during the treatment of pancreatic cancerRobert A Wolff, Andrea Wang-Gillam, Hector Alvarez, et al.
Nature Communications|March 21, 2024
Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancerAshenafi Bulle, Peng Liu, Kuljeet Seehra, et al.
Cancer Discovery|December 17, 2017
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J Sullivan, Jeffrey R Infante, Filip Janku, et al.
The Journal of Clinical Investigation|December 15, 2021
Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancersMark Yarchoan, Leslie Cope, Amanda N Ruggieri, et al.
The Lancet. Gastroenterology & Hepatology|December 4, 2025
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRAS<sup>G12C</sup> mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trialsJian Li, Zhenghang Wang, Jing Huang, et al.
Pageof 17

Showing results (151-160 of 167) with videos related to

Sort By:
Pageof 17
Cancer Cell|January 4, 2016
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth SuppressionTikvah K Hayes, Nicole F Neel, Chaoxin Hu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2019
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)Dung T Le, Vincent J Picozzi, Andrew H Ko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2022
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion StudyAndrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, et al.
The Lancet. Oncology|April 9, 2016
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trialTimothy M Nywening, Andrea Wang-Gillam, Dominic E Sanford, et al.
Cancer Communications (London, England)|October 2, 2025
Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trialsJian Li, Ting Deng, Yanhong Gu, et al.
Oncotarget|March 31, 2018
Dynamic changes during the treatment of pancreatic cancerRobert A Wolff, Andrea Wang-Gillam, Hector Alvarez, et al.
Nature Communications|March 21, 2024
Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancerAshenafi Bulle, Peng Liu, Kuljeet Seehra, et al.
Cancer Discovery|December 17, 2017
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J Sullivan, Jeffrey R Infante, Filip Janku, et al.
The Journal of Clinical Investigation|December 15, 2021
Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancersMark Yarchoan, Leslie Cope, Amanda N Ruggieri, et al.
The Lancet. Gastroenterology & Hepatology|December 4, 2025
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRAS<sup>G12C</sup> mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trialsJian Li, Zhenghang Wang, Jing Huang, et al.
Pageof 17